- Home
- KYMR vs BEAM Comparison
KYMR vs BEAM Comparison
Compare KYMR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- BEAM
- Stock Information
- Founded
- KYMR 2015
- BEAM 2017
- Country
- KYMR United States
- BEAM United States
- Employees
- KYMR N/A
- BEAM N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KYMR Health Care
- BEAM Health Care
- Exchange
- KYMR Nasdaq
- BEAM Nasdaq
- Market Cap
- KYMR 1.8B
- BEAM 1.8B
- IPO Year
- KYMR 2020
- BEAM 2020
- Fundamental
- Price
- KYMR $29.64
- BEAM $15.83
- Analyst Decision
- KYMR Buy
- BEAM Strong Buy
- Analyst Count
- KYMR 15
- BEAM 11
- Target Price
- KYMR $55.47
- BEAM $48.90
- AVG Volume (30 Days)
- KYMR 650.3K
- BEAM 2.0M
- Earning Date
- KYMR 05-09-2025
- BEAM 05-06-2025
- Dividend Yield
- KYMR N/A
- BEAM N/A
- EPS Growth
- KYMR N/A
- BEAM N/A
- EPS
- KYMR N/A
- BEAM N/A
- Revenue
- KYMR $58,885,000.00
- BEAM $63,578,000.00
- Revenue This Year
- KYMR $32.80
- BEAM N/A
- Revenue Next Year
- KYMR $8.88
- BEAM $10.59
- P/E Ratio
- KYMR N/A
- BEAM N/A
- Revenue Growth
- KYMR N/A
- BEAM N/A
- 52 Week Low
- KYMR $19.45
- BEAM $13.53
- 52 Week High
- KYMR $53.27
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- KYMR 48.27
- BEAM 36.15
- Support Level
- KYMR $28.06
- BEAM $16.61
- Resistance Level
- KYMR $30.28
- BEAM $17.47
- Average True Range (ATR)
- KYMR 1.65
- BEAM 0.91
- MACD
- KYMR -0.19
- BEAM -0.08
- Stochastic Oscillator
- KYMR 27.96
- BEAM 12.63
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.